



Ad-hoc-News

## **Marinomed Biotech AG signs financing agreement with Nice & Green S.A. to advance its scientific and clinical programs**

**Korneuburg, Austria, 4 October 2021** – Marinomed Biotech AG (VSE:MARI), an Austrian science-based biotech company with globally marketed therapeutics derived from innovative proprietary technology platforms, announces that it has secured financing in a total amount of up to € 5.4 million via a flexible Convertible Notes Funding Program (CNFP) from the Swiss investment firm Nice & Green S.A. The flexible financing provided by this program enables Marinomed to advance its scientific and clinical programs for its two proprietary assets, the virus blocking Carragelose technology and the Marinosolv platform for the solubilization of pharmaceutical compounds.

Under the terms of the agreement, Marinomed Biotech AG is entitled to issue up to 18 tranches of zero-coupon convertible bonds of up to € 300,000 per tranche during the contractual period of approximately 23 months. Nice & Green S.A. has committed to subscribe for those convertible notes and shall request the conversion into ordinary shares of the Company within a specific period after their issuance. As underlying for the CNFP serve up to 147,243 new no-par value bearer shares, which are available from the conditional capital approved by the Annual General Meeting on 17 June 2021.

In order to allow the issuance of the convertible notes (within the meaning of Section 174 of the Austrian Stock Corporation Act) under the CNFP exclusively to Nice & Green S.A., the Executive Board, by resolution as of today, has made use of the authorization granted by the Annual General Meeting of Shareholders of 17 June 2021 and excluded the subscription right, subject to the approval of the Supervisory Board.

+++ End of the ad hoc announcement +++

### **For further inquiries contact:**

#### **Marinomed Biotech AG**

Pascal Schmidt, CFO  
Hovengasse 25, 2100 Korneuburg, Austria  
T +43 2262 90300  
E-mail: [ir@marinomed.com](mailto:ir@marinomed.com)  
<http://www.marinomed.com>

#### **International Media and IR Contact**

MC Services AG  
Dr. Brigitte Keller, Dr. Regina Lutz  
T +49 89 210228 0  
**UK:** Shaun Brown  
M: +44 7867 515 918  
E-mail: [marinomed@mc-services.eu](mailto:marinomed@mc-services.eu)

### **Disclaimer**

This press release contains forward-looking statements, which are based on current views, expectations and projections of the management of Marinomed Biotech AG about future events. These forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results, performance or events to differ materially from those described in, or expressed or implied by, such statements. The current views, expectations and projections of the management of Marinomed Biotech AG may be identified by the context of such statements or words such as “anticipate,” “believe”, “estimate”, “expect”, “intend”, “plan”, “project” and “target”. Forward-looking statements are only valid as of the date they are made and Marinomed Biotech AG does not assume any obligation to update, review or revise any forward-looking statements contained in this press release whether as a result of new information, future developments or otherwise.